A search for the best NAD+ provider can mix prescription programs, infusion clinics, and oral supplements into one list. That makes the ranking easy to scan but difficult to interpret. This shortlist keeps the product category and the unanswered questions visible.
CoreAge Rx occupies the number-one paid featured position. The commercial order does not establish superior clinical outcomes. Our entries summarize public information checked September 23, 2026, with no independent patient testing or completed clinician review.
THE USEFUL DISTINCTION
Choose the question before comparing the offer: ingredient, route, evidence, clinical oversight, and cost are separate dimensions.
1. CoreAge Rx — paid featured injection service
CoreAge advertises a compounded NAD+ injectable program, clinician assessment, and a starting price of $93 per month. Its public product page links to a NAD-specific enrollment destination. Confirm the actual prescription, pharmacy, billing term, and follow-up arrangements before relying on the offer.
The CoreAge review identifies both the verified public details and the benefit claims that remain marketing rather than independently established outcomes. Its first position is purchased prominence, not a clinical score.
Evidence: CoreAge Rx: NAD+ injectable product page / CoreAge Rx: pharmacy information
2. AgelessRx — examine the introductory term
AgelessRx’s injection page advertises $79 for the first month on a three-month plan billed in full, followed by $149 per month. It also describes ongoing support and a compounding-pharmacy model. Ask for the complete first invoice and the renewal and cancellation terms.
Our AgelessRx review explains why its customer survey should not be read as a randomized trial or a personal probability of benefit. Product and pharmacy questions remain important alongside the price.
Evidence: AgelessRx: NAD+ injections / AgelessRx: NAD support catalog
3. Elysium Basis — a separate supplement category
Basis is an oral combination of NR and pterostilbene, not an injectable NAD+ service. Its published randomized trial measured safety, tolerability, and NAD-related biomarkers over eight weeks in older adults. That is not proof of longer life or evidence for a compounded injection.
Read the Basis review for study context and subscription terms. This entry broadens the research comparison while preserving the distinction between supplements and prescription preparations.
Evidence: Elysium: Basis product and subscription terms / Dellinger et al.: 2017 NRPT randomized trial
Questions that improve the comparison
Ask what was studied, whether it matches the sold product, and whether the measured outcome matches the benefit you hope for. Then investigate clinician authorization, pharmacy licensing, sterile preparation where relevant, and the actual financial commitment.
Use the safety explainer, cost guide, and study explorer. No position in this list establishes that a product is suitable for you, that it is FDA-approved, or that a proposed clinical outcome has been demonstrated.
Evidence: FDA: suitable ingredients for sterile compounding / FDA: compounding and approval / HHS: telehealth licensing
Open the source material
- CoreAge Rx: NAD+ injectable product page
Commercial description and starting price checked September 23, 2026. Benefit claims are not independent efficacy evidence.
- CoreAge Rx: pharmacy information
Company explanation of its pharmacy network; verify the actual dispensing pharmacy for a prescription.
- AgelessRx: NAD+ injections
Advertised $79 first month on a three-month plan billed in full, then $149 per month. Confirm final terms; surveys are not controlled trials.
- AgelessRx: NAD support catalog
Different routes are distinct products. Catalog claims do not establish equivalent clinical outcomes.
- Elysium: Basis product and subscription terms
Oral NR plus pterostilbene supplement, not injectable NAD+. Marketing and purchase terms are separate from clinical trial results.
- Dellinger et al.: 2017 NRPT randomized trial
120 adults aged 60–80, eight weeks; NAD+ biomarker and safety outcomes. Elysium funded the study; not evidence of longer life.
- FDA: suitable ingredients for sterile compounding
Specific NAD+ safety communication: food-grade material, contamination risk and reported adverse events.
- FDA: compounding and approval
Compounded drugs are not FDA-approved; ingredient evidence does not certify the finished preparation.
- HHS: telehealth licensing
General licensure guidance. Individual state availability must be checked directly.
